SBPH Spring Bank Pharmaceuticals Inc.

-0.3  -4%
Previous Close 6.95
Open 6.97
Price To Book 2.12
Market Cap 109346828
Shares 16,443,132
Volume 38,966
Short Ratio
Av. Daily Volume 48,777

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data presented at EASL April 12, 2019.
Inarigivir and Vemlidy - ACHIEVE
Hepatitis B (HBV)
Phase 2 to be initated pending funding.
SB 9200
Respiratory syncytial virus (RSV)
Phase 1/2 trial to be initiated 2H 2019.
SB 11285
Hepatocellular carcinoma
Phase 2 initial data due 2H 2019.
Inarigivir and NUCs
Hepatitis B (HBV)
Phase 2b top-line data due 2020 and 2021.
Inarigivir - (CATALYST 1 and CATALYST 2)
Hepatitis B (HBV)
Full data due at the Science of HBV Cure meeting in Singapore June 7-8, 2019
Inarigivir 400mg
Healthy volunteers

Latest News

  1. Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update
  2. Spring Bank Announces Positive Results from the Recently Completed Phase 2 Chronic Hepatitis B ACHIEVE Trial and Additional Inarigivir Studies
  3. Spring Bank to Host a Conference Call to Discuss Inarigivir Data Presented at the International Liver Congress™ (EASL 2019)
  4. Spring Bank Announces Inarigivir Abstracts Accepted for Oral and Poster Presentations at The International Liver Congress™ (EASL 2019)
  5. Spring Bank Pharmaceuticals to Participate in Jefferies 2019 HBV Summit
  6. Edited Transcript of SBPH earnings conference call or presentation 11-Mar-19 12:00pm GMT
  7. Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights
  8. Spring Bank Pharmaceuticals, Inc. to Host Earnings Call
  9. Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2018 Results on Monday, March 11
  10. Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development
  11. Spring Bank Pharmaceuticals Appoints Scott Smith as Chairman of the Board
  12. Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory Therapeutics
  13. Spring Bank Announces Additional Pre-Clinical Data on Its Second-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
  14. Spring Bank Announces Additional Inarigivir Results at AASLD Conference
  15. Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences
  16. Spring Bank Announces Three Poster Presentations on Its Next-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy